PSNL - Personalis Inc logo

PSNL

Personalis Inc

Personalis, Inc. develops genomic tests and services for cancer diagnosis and monitoring, including liquid biopsies and tumor profiling. It supports pharmaceutical companies and clinics in personalized therapy development, biomarker discovery, and clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$724today

Score Overview

1 Year
Score
Net Growth-31.88%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth0.03%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.2
Net Growth-64.32%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-18.51%
Rev Trend60%
Revenue Consistencyโ€”
All Time
Score
Net Growth-327.28%
Net Trend43%
Net Income Consistency
Rev Growth6.84%
Rev Trend71%
Revenue Consistency

See the full market ranking โ†’

Personalis Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 78M to $ 69M and net income went from -$ 41M to -$ 81M. Revenue increased in 3 of those 5 years; net income in 3.

Personalis Inc currently holds a 5-year HDB Score of 4.2 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 14.21โ€”
1 Year2025-08-12
$ 4.57210.94%
5 Years2021-08-12
$ 19.63-27.61%
All Time2019-06-20
$ 28.49-50.12%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 69M-$ 107M$ 212M
2025$ 69M-$ 81M$ 239M
2024$ 84M-$ 81M$ 185M
2023$ 73M-$ 108M$ 114M
2022$ 65M-$ 113M$ 167M
2021$ 85M-$ 65M$ 287M
2020$ 78M-$ 41M$ 203M
IPO2019$ 65M-$ 25M$ 128M

Explore beyond PSNL

You're looking at Personalis Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies